Why Novavax Stock Is Soaring Today
Shares of flu vaccine researcher Novavax (NASDAQ: NVAX) shot up 13.7% in early trading Tuesday after a positive analyst note out of Citigroup predicted "strong market opportunities" for the company's new NanoFlu nanoparticle-based flu vaccine. At last report, however, Novavax shares were spotted retracing their gains -- but still up 6.9% as of 11:40 a.m. EDT.
Image source: Getty Images.
Citigroup gave its stamp of approval to Novavax stock, calling NanoFlu "underappreciated by the Street." According to the analyst, Novavax shares that currently trade for just $1.09 apiece could shoot up as high as $1.60 per share within a year.
Source: Fool.com
Novavax Inc. Aktie
10,77 €
-3,00 %
Einige Buy-Einschätzungen dominieren bei Novavax Inc. gegenüber Sell-Einschätzungen.
Das Community-Kursziel von 21 € für Novavax Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 10.77 € hin.
